Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review (Q34112596)

31 July 2017

Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review (English)

1 reference

cost-effectiveness analysis

31 July 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

63616

1 reference

1 reference

Elise P Jansma

3

0 references

author name string

Mathilda L Bongers

1

1 reference

31 July 2017

Veerle M H Coupé

2

1 reference

31 July 2017

Egbert F Smit

4

1 reference

31 July 2017

Carin A Uyl-de Groot

5

1 reference

31 July 2017

1 January 2012

1 reference

31 July 2017

1 reference

31 July 2017

30

1 reference

31 July 2017

1

1 reference

31 July 2017

17-34

1 reference

https://scigraph.springernature.com/pub.10.2165/11595000-000000000-00000

31 July 2017

0 references

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Review of guidelines for good practice in decision-analytic modelling in health technology assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Economics of treatments for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Productivity costs of cancer mortality in the United States: 2000-2020

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

A review and meta-analysis of utility values for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Systematic reviews of economic evaluations: utility or futility?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

Best supportive care in lung cancer trials is inadequately described: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595000-000000000-00000

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

12 December 2020

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

12 December 2020

Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece

1 reference

12 December 2020

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

1 reference

12 December 2020

10.2165/11595000-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference